Literature DB >> 10155337

Prescribing trends and pharmacoeconomic considerations in the treatment of arrhythmias. Focus on atrial fibrillation and flutter.

B G Phillips1, J L Bauman.   

Abstract

Considerable progress has been made regarding the treatment of atrial fibrillation and atrial flutter. However, controversies still exist with respect to the therapy of choice for ventricular rate control, requirements for long term preventive therapy, and the place of surgical and ablation alternatives. Surrounding these controversies also lies a paucity of pharmacoeconomic studies, which limits delineation of the most cost-effective therapy for patients with atrial fibrillation and atrial flutter. This article reviews prescribing trends in the US for antiarrhythmic agents, and the available pharmacoeconomic studies that have specifically addressed the treatment of atrial fibrillation and atrial flutter.

Entities:  

Mesh：

Year:  1995        PMID： 10155337     DOI： 10.2165/00019053-199507060-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


  23 in total

1.  A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study.

Authors:  K A Ellenbogen; V C Dias; V J Plumb; J T Heywood; D M Mirvis
Journal:  J Am Coll Cardiol       Date:  1991-10       Impact factor: 24.094

2.  Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter.

Authors:  A T Gosselink; H J Crijns; I C Van Gelder; H Hillige; A C Wiesfeld; K I Lie
Journal:  JAMA       Date:  1992-06-24       Impact factor: 56.272

3.  Preliminary report of the Stroke Prevention in Atrial Fibrillation Study.

Authors: 
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

4.  Treatment of ventricular arrhythmias by United States cardiologists: a survey before the Cardiac Arrhythmia Suppression Trial results were available.

Authors:  J Morganroth; J T Bigger; J L Anderson
Journal:  Am J Cardiol       Date:  1990-01-01       Impact factor: 2.778

5.  How the university cardiologist treats ventricular premature beats: a nationwide survey of 65 University Medical Centers.

Authors:  S C Vlay
Journal:  Am Heart J       Date:  1985-10       Impact factor: 4.749

6.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

7.  Physician practice in the management of patients with uncomplicated myocardial infarction: changes in the past decade.

Authors:  N K Wenger; H K Hellerstein; H Blackburn; S J Castranova
Journal:  Circulation       Date:  1982-03       Impact factor: 29.690

8.  Outpatient antiarrhythmic drug use from 1970 through 1986.

Authors:  L K Hine; T P Gross; D L Kennedy
Journal:  Arch Intern Med       Date:  1989-07

9.  Verapamil infusions in the treatment of atrial tachyarrhythmias.

Authors:  R A Barbarash; J L Bauman; A A Lukazewski; J P Srebro; S Rich
Journal:  Crit Care Med       Date:  1986-10       Impact factor: 7.598

10.  Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group.

Authors:  D M Salerno; V C Dias; R E Kleiger; V H Tschida; R J Sung; M Sami; L V Giorgi
Journal:  Am J Cardiol       Date:  1989-05-01       Impact factor: 2.778
View more
  2 in total

Review 1.  The use of drugs for cardioversion of recent onset atrial fibrillation and flutter. Focus on ibutilide.

Authors:  O A Obel; A J Camm
Journal:  Drugs Aging       Date:  1998-06       Impact factor: 3.923

2.  Effects of Amiodarone and N-desethylamiodarone on Cardiac Voltage-Gated Sodium Channels.

Authors:  Mohammad-Reza Ghovanloo; Mena Abdelsayed; Peter C Ruben
Journal:  Front Pharmacol       Date:  2016-03-01       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.